Cervavac and gardasil comparison
Reading File
Searching the Web
Cervavac vs Gardasil HPV vaccine comparison 2024 2025
Searching PubMed
Cervavac HPV vaccine immunogenicity efficacy
Reading Article
PMID: 37949086
Reading Web Page
https://www.mdpi.com/2076-393X/14/2/140
Finding Sources
Here is a detailed comparison of Cervavac and Gardasil:
Cervavac vs. Gardasil - HPV Vaccine Comparison
Overview
| Feature | Cervavac | Gardasil (4-valent) | Gardasil 9 |
|---|---|---|---|
| Manufacturer | Serum Institute of India (SIIPL) | Merck Sharp & Dohme | Merck Sharp & Dohme |
| Origin country | India | USA/Netherlands | USA |
| Valency | Quadrivalent | Quadrivalent | Nonavalent |
| Approval year | 2022 (DCGI, India) | 2006 (FDA) | 2014 (FDA) |
| WHO Prequalification | Not prequalified (as of 2025) | WHO prequalified (2009) | WHO prequalified (2018) |
| Technology platform | VLP (yeast-derived) | VLP (yeast-derived) | VLP (yeast-derived) |
HPV Types Covered
| Vaccine | Types Covered | Protection Against |
|---|---|---|
| Cervavac | 6, 11, 16, 18 | ~70% cervical cancers + genital warts |
| Gardasil (4v) | 6, 11, 16, 18 | ~70% cervical cancers + genital warts |
| Gardasil 9 | 6, 11, 16, 18, 31, 33, 45, 52, 58 | ~90% cervical cancers + genital warts |
Both Cervavac and Gardasil 4v cover exactly the same HPV types. Gardasil 9 has broader coverage.
Immunogenicity (Key Clinical Trial Data)
The pivotal Phase II/III trial published in The Lancet Oncology (2023) directly compared Cervavac vs. Gardasil in India across 12 tertiary care hospitals (n = 2,307 participants):
- Non-inferiority established: Cervavac generated GMT (geometric mean titres) for all 4 HPV types (6, 11, 16, 18) that were non-inferior to Gardasil in the 9-14 year age group (using 2-dose schedule at months 0 and 6).
- Age groups studied: 9-14 years (2-dose) and 15-26 years (3-dose).
- Males included: Boys aged 9-14 years received Cervavac in open-label fashion - a notable inclusion for an Indian trial.
- The non-inferiority margin used was a lower bound of the 98.75% CI of the GMT ratio ≥ 0.67.
A 2025 state-of-the-art review in Vaccines (MDPI) confirmed: "Cervavac showed non-inferior immunogenicity compared with established vaccines," but noted that direct long-term clinical efficacy data on disease prevention are not yet available - protection is inferred from immunological equivalence.
Dosing Schedule
| Age Group | Cervavac | Gardasil (4v) |
|---|---|---|
| 9-14 years | 2 doses (0 and 6 months) | 2 doses (0 and 6-12 months) |
| 15 years and older | 3 doses (0, 2, 6 months) | 3 doses (0, 2, 6 months) |
| Males (9-14 y) | 2 doses | 2 doses |
Both vaccines require completion of the series with the same product - switching mid-course is not recommended for Cervavac, and there are no interchangeability data for Gardasil (4v) with Cervavac.
Safety Profile
From the Lancet Oncology Phase 2/3 trial:
- Both vaccines had comparable safety profiles.
- Most adverse events were local reactions (injection site pain, swelling, redness) and mild systemic events (fever, headache).
- No significant difference in serious adverse events between the two vaccines.
Cost and Access
| Factor | Cervavac | Gardasil |
|---|---|---|
| Price (India) | ~INR 2,000 per dose (significantly lower) | ~INR 3,000-4,000 per dose |
| Target market | LMIC countries, especially India | Global; higher-income markets |
| Purpose | To improve vaccine access and affordability in India and LMICs | Established global brand |
Cervavac was developed specifically to address affordability barriers in low- and middle-income countries (LMICs). India's national immunization program began incorporating Cervavac to expand access.
Key Differences Summarized
- Same HPV coverage: Both Cervavac and Gardasil 4v protect against the same 4 HPV types (6, 11, 16, 18). Gardasil 9 offers broader protection.
- Proven non-inferior immunogenicity: Cervavac is not inferior to Gardasil in head-to-head trials.
- No long-term efficacy data yet: Cervavac lacks the decades of real-world effectiveness data Gardasil has accumulated - protection is extrapolated from immunogenicity equivalence.
- WHO prequalification: Gardasil is WHO-prequalified; Cervavac is not (as of mid-2025), limiting its use in UN-procured vaccination campaigns.
- Cost advantage: Cervavac is significantly cheaper, making it the preferred option in India's public health immunization efforts.
- Interchangeability: Not recommended between the two - complete the series with whichever vaccine you start.
Bottom Line
Cervavac is a clinically validated, affordable Indian alternative to Gardasil 4v with identical HPV type coverage and proven immunological equivalence. For maximum HPV coverage (including types 31, 33, 45, 52, 58), Gardasil 9 remains the gold standard globally where affordability is not a barrier. The Lancet Oncology RCT (PMID: 37949086) is the key evidence base establishing Cervavac's non-inferiority.
This is a shared conversation. Sign in to Orris to start your own chat.